Pearson PLC (PSON.L)
24 Jun 2016
June 9 Britain's FTSE 100 index is seen opening down 20 points, or 0.3 percent, on Thursday, according to financial bookmakers, with futures down about 0.25 percent ahead of the cash market open. For more on the factors affecting European stocks, please click on
June 9 Britain's FTSE 100 index is seen opening down 20 points, or 0.3 percent, on Thursday, according to financial bookmakers. For more on the factors affecting European stocks, please click on * The UK blue chip index closed up 16.99 points, or 0.3 percent, at 6,285.21 points on Wednesday, with a recovery in commodities prices underpinning basic resources and energy stocks. * VODAFONE: Britain's Vodafone Group Plc on Thursday announced an effective takeover of leadin
SAO PAULO, June 8 Pearson Plc is looking at several possible acquisitions in Brazil amid a wave of merger talks, an executive told Reuters, as the British education company aims to take advantage of a favorable exchange rate in a market where it is fast expanding.
* Under separation agreement with former CEO pearson, he will provide consulting services to company through december 31, 2017
April 29 Valeant Pharmaceuticals International Inc :
LONDON - The yen hit an 18-month high as investors wager the Bank of Japan might be done adding fresh stimulus to the economy, culminating in a sharp rise on the week that dragged stocks around the world lower. (GLOBAL-MARKETS/ (WRAPUP 5), moved, by Jamie McGeever, 710 words)
* Says sentiment improving in some markets (Adds CEO comments, share price, analyst reaction)
LONDON, April 29 Pearson Plc, the British education company struggling to cope with a downturn in its biggest markets, reported a 4 percent fall in first-quarter underlying sales due to weak assessment revenues in the United States and Britain.
WASHINGTON/NEW YORK Activist investor William Ackman promised U.S. lawmakers on Wednesday that he will urge the board of Valeant Pharmaceuticals to reduce the high prices of four life-saving drugs that are now at the heart of two congressional probes.
WASHINGTON, April 27 Outgoing Valeant Pharmaceuticals Chief Executive Michael Pearson plans to tell a U.S. Senate panel on Wednesday that he regrets his decision to acquire and jack up the price of two life-saving heart drugs, saying it was all a "mistake."